Trastuzumab (Herceptin) Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities -- The Oncologist

Note: Trastuzumab is also known as Herceptin "Based on these considerations, it would be interesting if Extra and colleagues could reanalyze their data by distinguishing patients stopping trastuzumab according to whether or not they had "equal opportunities" to patients continuing trastuzumab beyond progression." (The Oncologist) Editor's note: Dr. Extra was invited to reply but declined comment.

Hereditary Cancer in Clinical Practice | Full text | Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management

Table 2:

Median age and range at diagnosis of Lynch syndrome associated cancer

                                      MLH1        MSH2           MSH6

Colorectal cancer 47 (25-79) 44 (20-82) 53 (32-84)

Endometrial cancer 51 (46-54) 46 (36-55) 56 (47-67)

Ovarian carcinoma 52 (52-52) 47 (45-48) 49 (35-51)

Small bowel cancer 54 (54-54) 36 (23-49) -

Transitional cell carcinoma - 58 (32-59) -

"The aim of the present study was to calculate the cumulative risk
of LS related cancers in proven MLH1, MSH2 and MSH6 mutation carriers." 

"Furthermore, some studies have suggested that extracolonic cancers are more often observed in MSH2 mutation families compared to MLH1 mutation families."